Clincosm LogoSign in Get a demo

LAM-ROS: Metabolism Des LAM

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Unknown status
CT.gov ID
NCT02176109
Collaborator
(none)
80
Enrollment
1
Location
60
Duration (Months)
1.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study, the investigators study the prognostic role of oxidative stress metabolism and iron in Acute myeloid leukemia.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Primary goal of this study is to Evaluate the characteristics of regulatory networks of iron and redox balance in leukemic cells, to study the correlations between the prognosis of AML patients (in terms of response to induction chemotherapy and survival i) and metabolism of these markers. Secondary ones areto assess the impact of induction therapy on markers of oxidative stress and to correlate biological iron and redox metabolism with the molecular status of patients (eg Flt3/IDH/CEBPA/NPM...).

    Eligibility criteria are patients at diagnostic of de novo acute myeloid leukemia (promyelocytic excluded) aged from 18 to 100 years.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    80 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Rôle Pronostique Des métabolismes du Stress Oxydatif et du Fer Dans Les Leucémies Aiguës Myéloblastiques
    Study Start Date :
    Jun 1, 2013
    Anticipated Primary Completion Date :
    Jun 1, 2015
    Anticipated Study Completion Date :
    Jun 1, 2018

    Outcome Measures

    Primary Outcome Measures

    1. overall survival Event-free survival Response to induction chemotherapy, overalll survival, event-free survival [five years after the inclusion]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    de novo acute myeloid leukemic patient from 18 years to 99 years at diagnosis

    Exclusion Criteria:

    age under 18 years promelocytic leukemia secondary leukemia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Grenoble Grenoble Isere France 38043

    Sponsors and Collaborators

    • University Hospital, Grenoble

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Grenoble
    ClinicalTrials.gov Identifier:
    NCT02176109
    Other Study ID Numbers:
    • gre-lam-fer
    • Métabolismes des LAM
    First Posted:
    Jun 26, 2014
    Last Update Posted:
    Jun 26, 2014
    Last Verified:
    Jun 1, 2013

    Study Results

    No Results Posted as of Jun 26, 2014